261 related articles for article (PubMed ID: 37772558)
1. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
4. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
5. ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.
Huang Z; Hu X; Wei Y; Lai Y; Qi J; Pang J; Huang K; Li H; Cai P
PLoS One; 2024; 19(5):e0303909. PubMed ID: 38814950
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
9. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
11. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
13. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
Front Genet; 2022; 13():927046. PubMed ID: 35937984
[No Abstract] [Full Text] [Related]
14. Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.
Zeng P; Zhang X; Xiang T; Ling Z; Lin C; Diao H
Bioengineered; 2022 Feb; 13(2):3221-3239. PubMed ID: 35067176
[TBL] [Abstract][Full Text] [Related]
15. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis reveals TSPEAR as a prognostic biomarker in colorectal cancer.
Xue D; Peng H; Li Z; Xu J; Ma H; Dang Y; Li F; Wang G; Sun Q
J Cancer; 2024; 15(3):809-824. PubMed ID: 38213725
[No Abstract] [Full Text] [Related]
17. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
Front Immunol; 2022; 13():994828. PubMed ID: 36405728
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
19. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer.
He M; Yu J; Chen S; Mi H
Int J Gen Med; 2023; 16():5255-5269. PubMed ID: 38021043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]